EMBRACE1: Prostate Biorepository

Completed

Conditions studied: Prostate Cancer

In brief

The objective of this multi-center prospective observational clinical study is to evaluate the clinical performance of the Carisome Prostate assay as an aid in the diagnosis of prostate cancer in men that have been scheduled for a prostate biopsy. Primarily, results of the Carisome Prostate assay will be compared with pathology results of prostate biopsy procedures. Secondarily, the performance of the Carisome Prostate test will be compared to the current standard of care for the detection of prostate cancer.

Key facts

Study ID

NCT01499381

Run by

Caris Science, Inc.

People needed

1290

Starts

2011-12-01

Expected to finish

2012-07-01

Last updated by the study team

2016-06-09

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Men scheduled for a routine prostate biopsy expected to produce a pathology evaluation and report
• Blood draw within 7 days prior to scheduled prostate biopsy procedure
• Blood draw on the day of but prior to biopsy

You may not qualify if…

• Any previous diagnosis of cancer with the exception of non-melanoma skin cancer
• Any prior or ongoing treatment for prostate cancer including prostatectomy or hormone therapy
• Prostate biopsy within one month of blood draw
• Previous enrollment in the Caris Life Sciences Biorepository

Where it is running

• Caris Science, Inc. — Phoenix, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.